Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 2:38 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,418 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active capsule Clear all
Not listed Phase 4 Interventional

Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease

NCT00941642
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Lovaza, placebo control
Drug
Lead sponsor
Huntington Medical Research Institutes
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Nov 1, 2026, 2:38 PM EST
Completed Phase 2 Interventional Results available

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease

NCT03084796
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
CHF 5259, Placebo, Tiotropium Bromide 18 µg Inhalation Capsule
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
112
States / cities
Birmingham, Alabama • Dothan, Alabama • Montgomery, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Nov 1, 2026, 2:38 PM EST
Completed Phase 2 Interventional

A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause

NCT06385795
View directory record Official record
Conditions
Menopause Syndrome, Menopause, Hot Flashes
Interventions
NOE-115
Drug
Lead sponsor
Noema Pharma AG
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
San Diego, California • Jacksonville, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Nov 1, 2026, 2:38 PM EST
Completed Phase 4 Interventional Results available

PO vs. IV Acetaminophen Given Perioperatively for 24 hr Post-op Pain Control Following Total Hip or Knee Replacement

NCT02244619
View directory record Official record
Conditions
Post-op Pain
Interventions
Oral acetaminophen, IV acetaminophen
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Nov 1, 2026, 2:38 PM EST
Completed Phase 3 Interventional Results available

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

NCT00368277
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Hydrochlorothiazide, Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2011 · Synced Nov 1, 2026, 2:38 PM EST
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain

NCT02476422
View directory record Official record
Conditions
Post Operative Dental Pain
Interventions
Diclofenac potassium, Ibuprofen, Placebo to ibuprofen, Placebo to diclofenac potassium
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Nov 1, 2026, 2:38 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of EQU-001 in Healthy Volunteers

NCT05004571
View directory record Official record
Conditions
Safety Issues
Interventions
EQU-001, Placebo
Drug
Lead sponsor
Equilibre Biopharmaceuticals B.V.
Industry
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Nov 1, 2026, 2:38 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of Nutritional Supplementation on Aerobic Performance and Fatigue

NCT02134756
View directory record Official record
Conditions
Performance, Fatigue
Interventions
NutraStem Active, NutraStem Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Nov 1, 2026, 2:38 PM EST
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT01892722
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 1, 2026, 2:38 PM EST
Completed Phase 2 Interventional Results available

Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension

NCT02279745
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ralinepag
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Nov 1, 2026, 2:38 PM EST
Completed Phase 2 Interventional Results available

Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention

NCT02896712
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Acceptance and Commitment Therapy (ACT), Drug Counseling (DC), Contingency Management (CM), Placebo, Modafinil
Behavioral · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Nov 1, 2026, 2:38 PM EST
Recruiting Phase 2 Interventional

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

NCT06233461
View directory record Official record
Conditions
Crohn's Disease
Interventions
TAK-279, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
30
States / cities
Murrieta, California • Orange, California • Clearwater, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 1, 2026, 2:38 PM EST
Withdrawn Early Phase 1 Interventional

Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth

NCT03420976
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth
Interventions
Novel Supplement Based Therapy
Dietary Supplement
Lead sponsor
Atrium Innovations
Industry
Eligibility
19 Years to 84 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Oxford, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Nov 1, 2026, 2:38 PM EST
Recruiting Phase 1Phase 2 Interventional

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

NCT03328078
View directory record Official record
Conditions
Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
Interventions
Emavusertib, Ibrutinib
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Duarte, California • Santa Monica, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 1, 2026, 2:38 PM EST
Completed Phase 4 Interventional

Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment

NCT03229889
View directory record Official record
Conditions
Nephrolithiasis
Interventions
Cialis 5Mg Tablet, Flomax 0.4Mg Capsule, Cialis + Flomax, Placebo
Drug · Combination Product
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 99 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Nov 1, 2026, 2:38 PM EST
Completed Not applicable Interventional Results available

Pregabalin for the Treatment of Pain After Posterior Spinal Fusions

NCT01366196
View directory record Official record
Conditions
Lumbar Spinal Fusions
Interventions
Pregabalin 150 mg, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
21 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Nov 1, 2026, 2:38 PM EST
Completed Phase 3 Interventional Results available

Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)

NCT00358462
View directory record Official record
Conditions
Urethritis
Interventions
Azithromycin, Doxycycline
Drug
Lead sponsor
University of Washington
Other
Eligibility
16 Years and older · Male only
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Nov 1, 2026, 2:38 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Multi-strain Probiotic Supplement for Digestive Comfort and Well-being in Healthy Women

NCT07831317
View directory record Official record
Conditions
Gastrointestinal Discomfort, Bloating
Interventions
Active: Multi-strain probiotic dietary supplement, Placebo: Placebo
Dietary Supplement
Lead sponsor
Daily Nouri
Industry
Eligibility
25 Years to 45 Years · Female only
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 1, 2026, 2:38 PM EST
Completed Phase 3 Interventional

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)

NCT01581203
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Asunaprevir (ASV), Daclatasvir (DCV), Pegylated-interferon alfa 2a (PegIFN), Ribavirin (RBV)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
18
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Nov 1, 2026, 2:38 PM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Human Experimental Models of Pain (HEMP)

NCT07549490
View directory record Official record
Conditions
Acute Pain
Interventions
Placebo, Naproxen, Pregabalin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 1, 2026, 2:38 PM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of Shatavari Root Extract for Premenstrual Syndrome in Women

NCT07441096
View directory record Official record
Conditions
Premenstrual Syndrome, Women Health
Interventions
Shatavari Root Extract, Placebo Capsule
Dietary Supplement · Other
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
18 Years to 40 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Nov 1, 2026, 2:38 PM EST
Withdrawn Phase 2 Interventional

Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia

NCT02197286
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cholecalciferol, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Nov 1, 2026, 2:38 PM EST
Completed Phase 2 Interventional

A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

NCT01594983
View directory record Official record
Conditions
Non Familial Chylocmicronemia Syndrome (Non-FCS)
Interventions
LCQ908, Fenofibrate, Fish Oil, Placebo of LCQ908, Placebo of fenofibrate, Placebo of fish oil
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Muscle Shoals, Alabama • Glendale, Arizona • Encinitas, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Nov 1, 2026, 2:38 PM EST
Completed Phase 3 Interventional Results available

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

NCT02520388
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Newport Beach, California • Bradenton, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Nov 1, 2026, 2:38 PM EST